Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Dysregulated Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling due to activation of tyrosine kinases is a common feature of myeloid malignancies. Here we report the first human disease-related mutations in the adaptor protein LNK, a negative regulator of JAK-STAT signaling, in 2 patients with JAK2 V617F-negative myeloproliferative neoplasms (MPNs). One patient exhibited a 5 base-pair deletion and missense mutation leading to a premature stop codon and loss of the pleckstrin homology (PH) and Src homology 2 (SH2) domains. A second patient had a missense mutation (E208Q) in the PH domain. BaF3-MPL cells transduced with these LNK mutants displayed augmented and sustained thrombopoietin-dependent growth and signaling. Primary samples from MPN patients bearing LNK mutations exhibited aberrant JAK-STAT activation, and cytokine-responsive CD34(+) early progenitors were abnormally abundant in both patients. These findings indicate that JAK-STAT activation due to loss of LNK negative feedback regulation is a novel mechanism of MPN pathogenesis.
Oh
Stephen T
ST
Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Dr., Stanford, CA 94305-5821, USA.
Simonds
Erin F
EF
Jones
Carol
C
Hale
Matthew B
MB
Goltsev
Yury
Y
Gibbs
Kenneth D
KD
Merker
Jason D
JD
Zehnder
James L
JL
Nolan
Garry P
GP
Gotlib
Jason
J
D048868:Adaptor Proteins, Signal Transducing; D002455:Cell Division / Q000502:physiology; D045744:Cell Line, Tumor; D018388:Codon, Terminator; D025461:Feedback, Physiological / Q000502:physiology; D017353:Gene Deletion; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D053614:Janus Kinase 2 / Q000378:metabolism; D020125:Mutation, Missense; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000378:metabolism*; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D050796:STAT3 Transcription Factor / Q000378:metabolism; D050799:STAT5 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*
D048868:Adaptor Proteins, Signal Transducing; D018388:Codon, Terminator; D047908:Intracellular Signaling Peptides and Proteins; D011506:Proteins; C490778:SH2B3 protein, human; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D050799:STAT5 Transcription Factor; C507924:JAK2 protein, human; D053614:Janus Kinase 2
PLoS Med. 2006 Jul;3(7):e270
16834459
Lancet. 2005 Mar 19-25;365(9464):1054-61
15781101
Nature. 2005 Apr 28;434(7037):1144-8
15793561
Cell. 2004 Jul 23;118(2):217-28
15260991
Eur J Haematol. 2006 Sep;77(3):210-6
16923108
Blood. 2007 Nov 1;110(9):3360-4
17693582
J Exp Med. 2004 Sep 6;200(5):569-80
15337790
Cancer Cell. 2005 Apr;7(4):387-97
15837627
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6224-9
16603627
Blood. 2006 Nov 15;108(10):3472-6
16868251
J Clin Invest. 2008 Aug;118(8):2832-44
18618018
Blood. 2007 Jul 1;110(1):354-9
17376889
J Exp Med. 2002 Jun 17;195(12):1599-611
12070287
N Engl J Med. 2007 Feb 1;356(5):459-68
17267906
J Exp Med. 2002 Jan 21;195(2):151-60
11805142
Cancer Cell. 2008 Oct 7;14(4):335-43
18835035
Blood. 2005 Jun 15;105(12):4604-12
15705783
Leukemia. 2006 Oct;20(10):1800-8
16871275
Sci STKE. 2001 Jun 05;2001(85):pe1
11752654
Blood. 2006 Apr 1;107(7):2968-75
16332975
N Engl J Med. 2005 Apr 28;352(17):1779-90
15858187